FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bioverativ's Free Cash Flow for the
three
months ended in Dec. 2017 was $212 Mil. Bioverativ's Revenue for the
three
months ended in Dec. 2017 was $329 Mil. Therefore, Bioverativ's FCF Margin % for the quarter that ended in Dec. 2017 was 64.37%.
The historical rank and industry rank for Bioverativ's FCF Margin % or its related term are showing as below:
BIVV'
s FCF Margin % Range Over the Past 10 Years
Min: 0 Med: 0 Max: 49.43
Current: 49.43
During the past 5 years, the highest FCF Margin % of Bioverativ was 49.43%. The lowest was 0.00%. And the median was 0.00%.
BIVV's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -141.21
vs BIVV: 49.43
Bioverativ FCF Margin % Historical Data
The historical data trend for Bioverativ's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bioverativ's FCF Margin %
For the Biotechnology subindustry, Bioverativ's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioverativ's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bioverativ's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Bioverativ's FCF Margin % falls into.
Bioverativ FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
Bioverativ's FCF Margin for the fiscal year that ended in Dec. 2017 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioverativ FCF Margin % Related Terms
Thank you for viewing the detailed overview of Bioverativ's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Bioverativ Inc is a biotech focused on rare blood disorders and has two marketed hemophilia products: Eloctate (hemophilia A) and Alprolix (hemophilia B). Bioverativ spun off from Biogen in February 2017. Bioverativ's partner Swedish Orphan Biovitrum holds rights to these therapies and pipeline hemophilia therapies in many markets outside the U.S. Bioverativ is building a pipeline in rare blood-related disorders, such as TNT009 (part of the True North acquisition) in cold agglutinin disease and other hematology-focused drug candidates. Sanofi's pending acquisition of Bioverativ was announced in January 2018.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BIVV has been successfully added to your 